258 related articles for article (PubMed ID: 21901415)
1. Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD.
Becker A; Roessner V; Breuer D; Döpfner M; Rothenberger A
Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S267-75. PubMed ID: 21901415
[TBL] [Abstract][Full Text] [Related]
2. An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence.
Rothenberger A; Becker A; Breuer D; Döpfner M
Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S257-65. PubMed ID: 21901416
[TBL] [Abstract][Full Text] [Related]
3. An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes.
Döpfner M; Breuer D; Walter D; Rothenberger A
Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S277-88. PubMed ID: 21901414
[TBL] [Abstract][Full Text] [Related]
4. What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale.
Görtz-Dorten A; Breuer D; Hautmann C; Rothenberger A; Döpfner M
Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S297-307. PubMed ID: 21901412
[TBL] [Abstract][Full Text] [Related]
5. Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings.
Breuer D; Görtz-Dorten A; Rothenberger A; Döpfner M
Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S289-96. PubMed ID: 21901413
[TBL] [Abstract][Full Text] [Related]
6. An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety.
Döpfner M; Görtz-Dorten A; Breuer D; Rothenberger A
Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S243-55. PubMed ID: 21901417
[TBL] [Abstract][Full Text] [Related]
7. Effects of Discontinuing Methylphenidate on Strengths and Difficulties, Quality of Life and Parenting Stress.
Matthijssen AM; Dietrich A; Bierens M; Kleine Deters R; van de Loo-Neus GHH; van den Hoofdakker BJ; Buitelaar JK; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):159-165. PubMed ID: 31880479
[No Abstract] [Full Text] [Related]
8. Effects of switching to once-daily modified-release methylphenidate from previous treatment with other psychostimulants in children and adolescents with ADHD: an observational study with clinician, parent, and teacher evaluations.
Frölich J; Breuer D; Görtz-Dorten A; Amonn F; Fischer R; Döpfner M
J Clin Psychopharmacol; 2014 Feb; 34(1):168-71. PubMed ID: 24346749
[No Abstract] [Full Text] [Related]
9. An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate.
Hautmann C; Rothenberger A; Döpfner M
BMC Psychiatry; 2013 Sep; 13():219. PubMed ID: 24004962
[TBL] [Abstract][Full Text] [Related]
10. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
[TBL] [Abstract][Full Text] [Related]
11. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
Yoo HK; Park S; Wang HR; Lee JS; Kim K; Paik KW; Yum MS; Ko TS
Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067
[TBL] [Abstract][Full Text] [Related]
12. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
[TBL] [Abstract][Full Text] [Related]
13. Association between quality of life and treatment response in children with attention Deficit Hyperactivity Disorder and their parents.
van der Kolk A; Bouwmans CA; Schawo SJ; Buitelaar JK; van Agthoven M; Hakkaart-van Roijen L
J Ment Health Policy Econ; 2014 Sep; 17(3):119-29. PubMed ID: 25543115
[TBL] [Abstract][Full Text] [Related]
14. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
15. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
16. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B
Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214
[TBL] [Abstract][Full Text] [Related]
17. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
Remschmidt H; Hoare P; Ettrich C; Rothenberger A; Santosh P; Schmidt M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE; Medori R
Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):297-304. PubMed ID: 16220213
[TBL] [Abstract][Full Text] [Related]
18. Quality of life of methylphenidate treatment-responsive adolescents with attention-deficit/hyperactivity disorder.
Yang PC; Lung FW; Chiou SS; Yen CF; Fuh JL
Kaohsiung J Med Sci; 2012 May; 28(5):279-84. PubMed ID: 22531308
[TBL] [Abstract][Full Text] [Related]
19. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
[TBL] [Abstract][Full Text] [Related]
20. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
